Mitral Valve in Hypertrophic Cardiomyopathy (NCT03877731) | Clinical Trial Compass
CompletedNot Applicable
Mitral Valve in Hypertrophic Cardiomyopathy
Russia100 participantsStarted 2006-12-01
Plain-language summary
The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve outflow tract obstruction in such patients
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \>18 years
* Signed informed consent to participate in the study
* For patients with hypertrophic cardiomyopathy only: resting or latent peak left ventricular outflow tract gradient \>50 mmHg, NYHA class III-IV
* For patients with arterial hypertension only: hystory of arterial pressure increase \>140/90 mmHg, increased left vantricular wall thickness (\>10 mm) and myocardial mass indexed to BSA (\>95 g/m2 for women and \>115 g/m2 for men), as assessed by 2D transthoracic echocardiography
Exclusion Criteria:
* Age \< 18 years
* Persistent form of atrial fibrillation
* Intrinsic mitral or aortic valve disease
* Coronary artery disease
* Reduced left ventricular ejection fraction
* For control group only: presence of any structural heart disease
What they're measuring
1
Event-free survival
Timeframe: 5 years
Trial details
NCT IDNCT03877731
SponsorTomsk National Research Medical Center of the Russian Academy of Sciences